Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. - AlzForum Alzheimer Research Paper of the Week


	Current Papers
	ARF Recommends
	Milestone Papers
	Search All Papers
	Search Comments


	Research News
	Drug News
	Conference News


	AD Hypotheses
		AlzSWAN
		Current Hypotheses
		Hypothesis Factory
	Forums
		Live Discussions
		Virtual Conferences
		Interviews
	Enabling Technologies
		Workshops
		Research Tools
	Compendia
		AlzGene
		AlzRisk
		Antibodies
		Biomarkers
		Mutations
		Protocols
		Research Models
		Video Gallery
	Resources
		Bulletin Boards
		Conference Calendar
		Grants
		Jobs


	Overview
	Diagnosis/Genetics
	Research
	News
	Profiles
	Clinics


	Companies
	Tutorial
	Drugs in Clinical Trials


	About Alzheimer's
		FAQs
	Diagnosis
		Clinical Guidelines
		Tests
		Brain Banks
	Treatment
		Drugs and Therapies
	Caregiving
		Patient Care
		Support Directory
		AD Experiences


	Member Directory
	Researcher Profiles
	Institutes and Labs


	Mission
	ARF Team
	ARF Awards
	Advisory Board
	Sponsors
	Partnerships
	Fan Mail
	Support Us

Home: Papers of the Week

Annotation

	Price JL, McKeel DW, Buckles VD, Roe CM, Xiong C, Grundman M, Hansen LA, Petersen RC, Parisi JE, Dickson DW, Smith CD, Davis DG, Schmitt FA, Markesbery WR, Kaye J, Kurlan R, Hulette C, Kurland BF, Higdon R, Kukull W, Morris JC. Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging. 2009 Jul;30(7):1026-36. PubMed Abstract, View on AlzSWAN

	Comments on Paper and Primary News

	Comment by: Takaomi Saido, ARF Advisor
	Submitted 25 April 2009 \| Permalink	Posted 25 April 2009
	I recommend this paper This paper, together with previous ones, provides basic AD researchers with significant insights into future strategies. View all comments by Takaomi Saido

	Comment by: Paul Coleman, ARF Advisor
	Submitted 29 April 2009 \| Permalink	Posted 29 April 2009
	I recommend this paper This paper adds substantial weight to the evidence for significant neuropathology in the absence of a clinical definition of Alzheimer disease. One wonders whether measures at the synaptic or molecular levels would show stronger association between the postmortem status of brain and sophisticated indices of behavioral capacity. View all comments by Paul Coleman

	Comment by: George Perry (Disclosure)
	Submitted 8 May 2009 \| Permalink	Posted 10 May 2009
	I recommend this paper

Submit a Comment on this Paper

Cast your vote and/or make a comment on this paper.

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name
*Last Name
Country or Territory:
*Login Email Address
*Password	Minimum of 8 characters
*Confirm Password
Stay signed in?

I recommend this paper

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:

*Enter the verification code you see in the picture below:

This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:	Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.

REAGENTS/MATERIAL:
The following antibodies were used in this paper:
Immunohistochemistry with monoclonal mouse anti-amyloid-beta (10D5) (gift of Athena Neurosciences and Elan Pharmaceuticals) and monoclonal mouse anti-paired helical filaments (PHF-1) (gift of Drs. Sharon Greenberg and Peter Davies, Albert Einstein Medical School, Bronx, NY)




			Print this page Email this page Alzforum News Papers of the Week Text size Share & Bookmark Del.icio.us Digg Facebook Google Newsvine








			Antibodies Cell Lines Collaborators Papers Research Participants